FinancialBuzz.com’s latest
The Buzz Show: Featuring Our Corporate News Recap on “Sonoma Pharmaceuticals Enters Partnership with Crown Laboratories”
Sonoma Pharmaceuticals (NASDAQ: SNOA) soared over 112% in premarket trading on after it entered into a license and supply agreement to launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products.
The agreement gives Crown Laboratories the exclusive rights to sell and market Sonoma’s Microcyn® technology dermal sprays and gels targeting itch and pain within the United States.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) sho